|Dr. Thomas J. Schall Ph.D.||Founder, Pres, CEO & Chairman||1.21M||2.58M||1959|
|Ms. Susan M. Kanaya||Exec. VP, Chief Financial & Admin. Officer, Sec. and Director||845.04k||N/A||1963|
|Mr. Tausif Butt||Exec. VP & COO||1.01M||N/A||1966|
|Dr. Rita I. Jain M.D.||Exec. VP, Chief Medical Officer & Exec. Employee Director||670.7k||N/A||1963|
|Dr. Markus J. Cappel Ph.D.||Chief Bus. Officer & Treasurer||643.58k||1.13M||1961|
|Mr. William S. Slattery||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Kari E. Leetch||Sr. VP of HR||N/A||N/A||N/A|
|Ms. Dalia R. Rayes||Sr. VP & Head of Commercial||N/A||N/A||N/A|
|Dr. Sangita Ghosh Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
ChemoCentryx, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 5; Compensation: 5.